1887
Research article Open Access
Like 0

Abstract

In this retrospective study we employed real-time polymerase chain reaction (PCR) to analyse the occurrence of Mycoplasma pneumoniae among upper and lower respiratory tract infections (RTI) in the Central Region of Slovenia between January 2006 and December 2014. We also used a culture and pyrosequencing approach to genotype strains and infer their potential macrolide resistance. Of a total 9,431 tested samples from in- and out-patient with RTI, 1,255 (13%) were found to be positive by M. pneumoniae PCR. The proportion of positive samples was 19% (947/5,092) among children (?16 years-old) and 7% (308/4,339) among adults (>16 years-old). Overall, among those PCR tested, the highest proportions of M. pneumoniae infections during the study period were observed in 2010 and 2014. In these two years, 18% (218/1,237) and 25% (721/2,844) of samples were positive respectively, indicating epidemic periods. From the 1,255 M. pneumoniae PCR-positive samples, 783 (614 from paediatric and 169 from adult patients) were successfully cultured. Of these, 40% (312/783) were constituted of strains belonging to the P1 type II genomic group, while 60% (469/783) contained strains of the P1 type I group. Two isolates comprised both P1 type I and II strains. Results of a genotype analysis by year, showed that the dominant M. pneumoniae P1 type during the 2010 epidemic was P1 type II (82% of isolates; 81/99), which was replaced by P1 type I in the 2014 epidemic (75%; 384/510). This observation could indicate that the two epidemics may have been driven by a type shift phenomenon, although both types remained present in the studied population during the assessed period of time. Only 1% of strains (7/783) were found to harbour an A2063G mutation in the 23S rRNA gene, which confers macrolide resistance, suggesting that the occurrence of M. pneumoniae macrolide resistance still seems to be sporadic in our geographic area.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2015.20.37.30018
2015-09-17
2017-11-25
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2015.20.37.30018
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/20/37/eurosurv-20-30018-3.html?itemId=/content/10.2807/1560-7917.ES.2015.20.37.30018&mimeType=html&fmt=ahah

References

  1. Hammerschlag MR. Mycoplasma pneumoniae infections. Curr Opin Infect Dis. 2001;14(2):181-6.  https://doi.org/10.1097/00001432-200104000-00012  PMID: 11979130 
  2. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008;32(6):956-73.  https://doi.org/10.1111/j.1574-6976.2008.00129.x  PMID: 18754792 
  3. McIntosh K. Community-acquired pneumonia in children. N Engl J Med. 2002;346(6):429-37.  https://doi.org/10.1056/NEJMra011994  PMID: 11832532 
  4. Defilippi A, Silvestri M, Tacchella A, Giacchino R, Melioli G, Di Marco E, et al. Epidemiology and clinical features of Mycoplasma pneumoniae infection in children. Respir Med. 2008;102(12):1762-8.  https://doi.org/10.1016/j.rmed.2008.06.022  PMID: 18703327 
  5. Howard LS, Sillis M, Pasteur MC, Kamath AV, Harrison BD. Microbiological profile of community-acquired pneumonia in adults over the last 20 years. J Infect. 2005;50(2):107-13.  https://doi.org/10.1016/j.jinf.2004.05.003  PMID: 15667910 
  6. Miyashita N, Ouchi K, Kawasaki K, Oda K, Kawai Y, Shimizu H, et al. Mycoplasma pneumoniae pneumonia in the elderly. Med Sci Monit. 2008;14(8):CR387-91. PMID: 18667994 
  7. Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J. 2009;28(8):693-6.  https://doi.org/10.1097/INF.0b013e31819e3f7a  PMID: 19633515 
  8. Rasmussen JN, Voldstedlund M, Andersen RL, Ellermann-Eriksen S, Jensen TG, Johansen HK, et al. Increased incidence of Mycoplasma pneumoniae infections detected by laboratory-based surveillance in Denmark in 2010. Euro Surveill. 2010;15(45):19708. PMID: 21087593 
  9. Chalker V, Stocki T, Mentasti M, Fleming D, Harrison T. Increased incidence of Mycoplasma pneumoniae infection in England and Wales in 2010: multiocus variable number tandem repeat analysis typing and macrolide susceptibility. Euro Surveill. 2011;16(19):19865. PMID: 21596009 
  10. Eun BW, Kim NH, Choi EH, Lee HJ. Mycoplasma pneumoniae in Korean children: the epidemiology of pneumonia over an 18-year period. J Infect. 2008;56(5):326-31.  https://doi.org/10.1016/j.jinf.2008.02.018  PMID: 18420275 
  11. Pereyre S, Charron A, Renaudin H, Bébéar C, Bébéar CM. First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years. J Clin Microbiol. 2007;45(11):3534-9.  https://doi.org/10.1128/JCM.01345-07  PMID: 17881549 
  12. Cousin A, Bertille DB, Alain C, Helene R, Christiane B. Analysis of RFLPs amplified cytadhesin P1 gene for epidemiological study of Mycoplasma pneumoniae. In: Programme and abstracts of the 10th International Congress of the International Organisation for Mycoplasmology (IOM). 1994; p. 494-5.
  13. Dorigo-Zetsma JW, Dankert J, Zaat SA. Genotyping of Mycoplasma pneumoniae clinical isolates reveals eight P1 subtypes within two genomic groups. J Clin Microbiol. 2000;38(3):965-70. PMID: 10698981 
  14. Uldum SA, Bangsborg JM, Gahrn-Hansen B, Ljung R, Mølvadgaard M, Føns Petersen R, et al. Epidemic of Mycoplasma pneumoniae infection in Denmark, 2010 and 2011. Euro Surveill. 2012;17(5):20073. PMID: 22321137 
  15. Dumke R, von Baum H, Lück PC, Jacobs E. Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect. 2010;16(6):613-6.  https://doi.org/10.1111/j.1469-0691.2009.02968.x  PMID: 19765022 
  16. Chironna M, Sallustio A, Esposito S, Perulli M, Chinellato I, Di Bari C, et al. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother. 2011;66(4):734-7.  https://doi.org/10.1093/jac/dkr003  PMID: 21393214 
  17. Peuchant O, Ménard A, Renaudin H, Morozumi M, Ubukata K, Bébéar CM, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother. 2009;64(1):52-8.  https://doi.org/10.1093/jac/dkp160  PMID: 19429926 
  18. Averbuch D, Hidalgo-Grass C, Moses AE, Engelhard D, Nir-Paz R. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis. 2011;17(6):1079-82.  https://doi.org/10.3201/eid/1706.101558  PMID: 21749775 
  19. Yamada M, Buller R, Bledsoe S, Storch GA. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis J. 2012;31(4):409-10.  https://doi.org/10.1097/INF.0b013e318247f3e0  PMID: 22209916 
  20. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, et al. Acute Respiratory Diseases Study Group. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2008;52(1):348-50.  https://doi.org/10.1128/AAC.00779-07  PMID: 17954691 
  21. Cao B, Zhao CJ, Yin YD, Zhao F, Song SF, Bai L, et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis. 2010;51(2):189-94.  https://doi.org/10.1086/653535  PMID: 20540621 
  22. Xin D, Mi Z, Han X, Qin L, Li J, Wei T, et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother. 2009;53(5):2158-9.  https://doi.org/10.1128/AAC.01563-08  PMID: 19273685 
  23. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother. 2009;53(5):2160-2.  https://doi.org/10.1128/AAC.01684-08  PMID: 19273684 
  24. Zhao F, Lv M, Tao X, Huang H, Zhang B, Zhang Z, et al. Antibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China. Antimicrob Agents Chemother. 2012;56(2):1108-9.  https://doi.org/10.1128/AAC.05627-11  PMID: 22106216 
  25. Kawai Y, Miyashita N, Yamaguchi T, Saitoh A, Kondoh E, Fujimoto H, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology. 2012;17(2):354-62.  https://doi.org/10.1111/j.1440-1843.2011.02102.x  PMID: 22077195 
  26. Bébéar CM, Pereyre S. Mechanisms of drug resistance in Mycoplasma pneumoniae. Curr Drug Targets Infect Disord. 2005;5(3):263-71.  https://doi.org/10.2174/1568005054880109  PMID: 16181145 
  27. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother. 2010;16(2):78-86.  https://doi.org/10.1007/s10156-009-0021-4  PMID: 20094751 
  28. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, et al. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn Microbiol Infect Dis. 2010;67(4):355-8.  https://doi.org/10.1016/j.diagmicrobio.2010.03.004  PMID: 20638604 
  29. Socan M, Marinic-Fiser N, Kraigher A, Kotnik A, Logar M. Microbial aetiology of community-acquired pneumonia in hospitalised patients. Eur J Clin Microbiol Infect Dis. 1999;18(11):777-82.  https://doi.org/10.1007/s100960050400  PMID: 10614951 
  30. Beović B, Bonac B, Kese D, Avsic-Zupanc T, Kreft S, Lesnicar G, et al. Aetiology and clinical presentation of mild community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis. 2003;22(10):584-91.  https://doi.org/10.1007/s10096-003-0997-0  PMID: 13680399 
  31. Population, statistical regions, Slovenia, annualy. Republic of Slovenia Statistical office RS. [Accessed 24 Jun 2015]. Available from: http://pxweb.stat.si/pxweb/Dialog/varval.asp?ma=05C2002E&ti=&path=../Database/Demographics/05_population/10_Number_Population/10_05C20_Population_stat_regije/&lang=1
  32. Waites KB, Rikihisa Y, Taylor-Robinson D. Mycoplasma and Ureaplasma. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, editors. Manual of clinical microbiology 8th edition. Washington DC: American Society for Microbiology Press; 2003. p. 972-90.
  33. Pereyre S, Guyot C, Renaudin H, Charron A, Bébéar C, Bébéar CM. In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2004;48(2):460-5.  https://doi.org/10.1128/AAC.48.2.460-465.2004  PMID: 14742195 
  34. Himmelreich R, Hilbert H, Plagens H, Pirkl E, Li BC, Herrmann R. Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae. Nucleic Acids Res. 1996;24(22):4420-49.  https://doi.org/10.1093/nar/24.22.4420  PMID: 8948633 
  35. Schwartz SB, Mitchell SL, Thurman KA, Wolff BJ, Winchell JM. Identification of P1 variants of Mycoplasma pneumoniae by use of high-resolution melt analysis. J Clin Microbiol. 2009;47(12):4117-20.  https://doi.org/10.1128/JCM.01696-09  PMID: 19828737 
  36. Lin C, Li S, Sun H, Zhao H, Feng Y, Cao L, et al. Nested PCR-linked capillary electrophoresis and single-strand conformation polymorphisms for detection of macrolide-resistant Mycoplasma pneumoniae in Beijing, China. J Clin Microbiol. 2010;48(12):4567-72.  https://doi.org/10.1128/JCM.00400-10  PMID: 20861333 
  37. Sasaki T, Kenri T, Okazaki N, Iseki M, Yamashita R, Shintani M, et al. Epidemiological study of Mycoplasma pneumoniae infections in japan based on PCR-restriction fragment length polymorphism of the P1 cytadhesin gene. J Clin Microbiol. 1996;34(2):447-9. PMID: 8789036 
  38. Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T, Ouchi K, et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother. 2004;48(12):4624-30.  https://doi.org/10.1128/AAC.48.12.4624-4630.2004  PMID: 15561835 
  39. Zhao F, Cao B, Li J, Song S, Tao X, Yin Y, et al. Sequence analysis of the p1 adhesin gene of Mycoplasma pneumoniae in clinical isolates collected in Beijing in 2008 to 2009. J Clin Microbiol. 2011;49(8):3000-3.  https://doi.org/10.1128/JCM.00105-11  PMID: 21697320 
  40. Spuesens EB, Hoogenboezem T, Sluijter M, Hartwig NG, van Rossum AM, Vink C. Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae by pyrosequencing. J Microbiol Methods. 2010;82(3):214-22.  https://doi.org/10.1016/j.mimet.2010.06.004  PMID: 20547188 
  41. Spuesens EB, Meijer A, Bierschenk D, Hoogenboezem T, Donker GA, Hartwig NG, et al. Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae in respiratory specimens collected between 1997 and 2008 in The Netherlands. J Clin Microbiol. 2012;50(6):1999-2004.  https://doi.org/10.1128/JCM.00400-12  PMID: 22495561 
  42. Lenglet A, Herrador Z, Magiorakos AP, Leitmeyer K, Coulombier DEuropean Working Group on Mycoplasma pneumoniae surveillance. Surveillance status and recent data for Mycoplasma pneumoniae infections in the European Union and European Economic Area, January 2012. Euro Surveill. 2012;17(5):20075. PMID: 22321134 
  43. Kenri T, Okazaki N, Yamazaki T, Narita M, Izumikawa K, Matsuoka M, et al. Genotyping analysis of Mycoplasma pneumoniae clinical strains in Japan between 1995 and 2005: type shift phenomenon of M. pneumoniae clinical strains. J Med Microbiol. 2008;57(Pt 4):469-75.  https://doi.org/10.1099/jmm.0.47634-0  PMID: 18349367 
  44. Diaz MH, Benitez AJ, Winchell JM. Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013. J Clin Microbiol. 2015;53(1):124-30.  https://doi.org/10.1128/JCM.02597-14  PMID: 25355769 
  45. Pereyre S, Charron A, Hidalgo-Grass C, Touati A, Moses AE, Nir-Paz R, et al. The spread of Mycoplasma pneumoniae is polyclonal in both an endemic setting in France and in an epidemic setting in Israel. PLoS ONE. 2012;7(6):e38585.  https://doi.org/10.1371/journal.pone.0038585  PMID: 22701675 
  46. Pečar-Čad S, Hribovšek T. 2012. Ambulantno predpisovanje zdravil v sloveniji po ACT klasifikaciji v letu 2011. [Outpatient prescription drugs in Slovenia according to The Anatomical Therapeutic Chemical (ATC) Classification System in 2011]. Ljubljana: Inštitut za varovanje zdravja republike Slovenije. [Accessed 7 Oct 2014]. Slovenian. Available from: http://www.nijz.si/sites/www.nijz.si/files/publikacije-datoteke/ambulantno_predpisovanje_zdravil_v_slo_po_atc_klasifikaciji_2011.pdf
  47. The European Surveillance System (TESSy) - Distribution of antimicrobial consumption by antimicrobial group. Stockholm: European Centre for Disease Prevention and Control. [Accessed 22 Jun 2015]. Available from: http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/esac-net-database/Pages/consumption-rates-by-country.aspx
/content/10.2807/1560-7917.ES.2015.20.37.30018
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error